Black lung treatment

Black Lung Treatment Available at the Lung Institute

Alternative treatment for black lung disease, or coal worker’s pneumoconiosis (CWP), is available at the Lung Institute. We are a first-of-its-kind cellular therapy center that specializes in administering this innovative therapy, which can potentially help people with lung disease breathe easier and improve their quality of life. While there is not yet a cure for black lung disease, cellular therapy may reduce lung inflammation as well as the severity of symptoms in certain patients.

Black lung is an occupational disease that occurs when coal dust is inhaled into the lungs over an extended period of time. The disease primarily affects workers in the coal mining industry, as its name suggests. While safety measures established in the 1970s substantially reduced the incidence of black lung, this condition is on the rise once again. Additionally, the risk of acquiring chronic bronchitis and chronic obstructive pulmonary disease (COPD) is higher for patients with black lung disease.

The Lung Institute offers black lung treatment in the form of cellular therapy. During this outpatient treatment, the patient’s own cells are harvested, processed in an onsite laboratory and reintroduced to the patient’s bloodstream in an effort to stimulate the body’s natural healing processes. Cells can be harvested through a simple blood draw, which are relatively painless. The treatment is provided over two days and has shown promising results. In fact, more than 80 percent of patients who have received cellular therapy at the Lung Institute report an enhancement in their quality of life.

Contact the Lung Institute today at (800) 729-3065 to speak with our compassionate medical team. We’ll be happy to answer any questions you may have about this alternative black lung treatment and help determine if cellular therapy is right for you.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.